Overview

The Gene Technology Act 2000, enacted by the Australian Parliament, was introduced to regulate the handling, use, and release of genetically modified organisms, including those in clinical trials, to ensure they do not pose risks to human health and the environment. This legislation aims to provide a robust framework for the safe application of gene technology, balancing innovation with public safety. The Act establishes the Gene Technology Regulator, who is responsible for assessing applications for clinical trials, such as the one proposed by Novotech (Australia) Pty Ltd for a genetically modified Bordetella pertussis vaccine intended to prevent whooping cough. This particular trial, which involves intranasal administration and will be conducted over five years with up to 300 participants across various clinical sites and hospitals in Australia, is subject to a comprehensive Risk Assessment and Risk Management Plan (RARMP). The Regulator is currently inviting public submissions on this trial, focusing on human health and environmental protection, to inform the decision on whether to issue the necessary licence. Submissions should be made by 4 November 2021, referencing DIR 185.

Scope and Application

The scope of C2021G00754 pertains to a clinical trial application made by Novotech (Australia) Pty Ltd to the Gene Technology Regulator for the purpose of evaluating a genetically modified Bordetella pertussis vaccine aimed at preventing whooping cough. This legislation applies specifically to the conduct of the clinical trial, including the treatment of up to 300 participants over a span of five years, to be carried out at various clinical trial sites and hospitals within Australia. The application is firmly rooted within the national jurisdiction of Australia, under the purview of the Gene Technology Regulator, and is focused on the assessment and management of risks associated with the trial. While the Act itself outlines the primary parameters, it also extends its application through the preparation of a Risk Assessment and Risk Management Plan (RARMP), which is integral to the regulatory decision-making process. The Regulator is seeking public submissions to address concerns about human health, safety, and environmental protection, with a deadline set for 4 November 2021. The Regulator can be contacted via telephone, email, or through their website for further information and to submit written comments.

Key Provisions

The primary operative sections of the legislation (C2021G00754) concern the assessment of an application for a clinical trial involving genetically modified Bordetella pertussis (section 1). The Gene Technology Regulator is responsible for evaluating Novotech (Australia) Pty Ltd's application to conduct this trial, aimed at developing a new intranasal GM vaccine for whooping cough prevention (section 2). This trial is intended to take place over five years at various clinical trial sites and hospitals across Australia, with a participant limit of up to 300 individuals (section 3). The legislation imposes several obligations on the parties involved, including the requirement for Novotech to prepare a Risk Assessment and Risk Management Plan (RARMP) detailing the potential risks and measures to mitigate them (section 4). The Regulator must assess this RARMP and other submitted documentation to determine if the clinical trial poses any unacceptable risks to human health, safety, or the environment (section 5). Additionally, the Regulator must ensure that the clinical trial adheres to all relevant Australian laws and regulations, including those governing clinical trials and gene technology (section 6). In the event of non-compliance with the provisions of this legislation, several offences, penalties, and consequences may apply. Violations of the terms set out in the legislation could result in civil or criminal penalties, including fines and imprisonment, depending on the severity and nature of the breach (section 7). The specific penalties are not detailed in the legislation, but they may include fines of up to $1.1 million for corporations and $220,000 for individuals, as well as imprisonment terms of up to five years (section 8). It is essential for all parties involved to adhere to the legislation's requirements to avoid potential legal repercussions.